CIK 0000907654 · Non-accelerated filer<br>Smaller reporting company
Oruka Therapeutics, Inc.
Sign in to watch- Ticker
- ORKA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 363855489
- Phone
- 650-606-7910
- Business address
- 855 OAK GROVE AVE., SUITE 100, MENLO PARK, CA, 94025
- Former names
- ARCA biopharma, Inc., NUVELO INC, HYSEQ INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,653,308
- in 17 filings, $20.2M under 10b5-1 plans
Net −$20,653,308. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Klein Lawrence Otto −$11.6M Chief Executive Officer sold 12% of stake
- Agarwal Arjun −$2.8M Senior Vice President, Finance sold 68% of stake
- Goncalves Joana −$2.0M Chief Medical Officer sold 41% of stake
- BALL KRISTINE M −$1.9M Director sold 100% of stake
- Quinlan Paul T −$1.7M General Counsel sold 40% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-11 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −8,000 | 84,917 | ||
| 2026-09-11 | Agarwal Arjun Senior Vice President, Finance | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −1,459 | 58,333 | ||
| 2026-09-01 | Sandler Laura Lee Chief Operating Officer | Option exercise 10b5-1 | +5,000 | $7.80 | $39K | 241,384 |
| 2026-09-01 | Sandler Laura Lee Chief Operating Officer | Sale 10b5-1 | −1,000 | $91.05 | $91K | 240,384 |
| 2026-09-01 | Sandler Laura Lee Chief Operating Officer | Sale 10b5-1 | −4,000 | $92.01 | $368K | 236,384 |
| 2026-09-01 | Sandler Laura Lee Chief Operating Officer | Option exercise · Employee Warrant (right to buy) 10b5-1 | −5,000 | 74,996 | ||
| 2026-09-01 | Klein Lawrence Otto Chief Executive Officer | Option exercise 10b5-1 | +75,000 | $7.80 | $585K | 1,000,580 |
| 2026-09-01 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −6,604 | $90.79 | $600K | 993,976 |
| 2026-09-01 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −63,596 | $91.90 | $5.8M | 930,380 |
| 2026-09-01 | Klein Lawrence Otto Chief Executive Officer | Sale 10b5-1 | −4,800 | $92.44 | $444K | 925,580 |
| 2026-09-01 | Klein Lawrence Otto Chief Executive Officer | Option exercise · Employee Warrant (right to buy) 10b5-1 | −75,000 | 1,553,513 | ||
| 2026-08-24 | Edwards Larry Todd Chief Commercial Officer | Grant or award | +100,000 | 100,000 | ||
| 2026-08-24 | Edwards Larry Todd Chief Commercial Officer | Grant or award · Employee Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Option exercise 10b5-1 | +3,500 | $6.84 | $24K | 36,218 |
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 39,718 |
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −900 | $109.65 | $99K | 38,818 |
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −300 | $110.52 | $33K | 38,518 |
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −3,320 | $112.01 | $372K | 35,198 |
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −2,480 | $112.56 | $279K | 32,718 |
| 2026-08-17 | Goncalves Joana Chief Medical Officer | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −3,500 | 197,063 |
Page 5 of 18 · 346 trades